1. home
  2. #tags
  3. Euro

Discover Latest #Euro News, Articles and Videos with Contenting

1. "EU Proposes New Rules on Digital Tax to Make Tech Giants Pay Their Share" - This article from Reuters discusses how the European Union's executive branch proposed new rules for digital taxation to ensure tech giants pay their fair share of taxes. The new rules are set to impact companies like Amazon, Apple, Facebook, and Google. 2. "Germany, France and Italy Sign Pact to Tax Digital Giants" - This article from the New York Times discusses how Germany, France, and Italy have signed a pact to tax digital companies such as Amazon, Apple, Facebook, and Google. The agreement is the first major step in the European Union's effort to tax tech giants. 3. "EU's New Digital Tax Plan: What You Need to Know" - This video from Euronews explains the European Union's new digital tax plan and how it will affect tech giants such as Amazon, Apple, Facebook, and Google. The video also explains the different aspects of the plan and how it will be implemented.

Vertex's Cystic Fibrosis Drug Alyftrek Gets FDA Approval - ForexTV

Vertex Pharmaceuticals Inc. (VRTX) announced on Friday that the U.S. Food and Drug Administration (FDA) has approved Alyftrek for the treatment of cystic fibrosis.Alyftrek is a cutting-edge, once-daily triple combination drug that modulates the cystic fibrosis transmembrane conductance regulator (CFTR) for patients aged six and older. It is specifically designed for individuals with at least one F508del mutation or other CFTR gene mutations that respond to Alyftrek."This approval marks our fifth CFTR modulator to receive FDA approval, representing a major milestone in our ongoing quest to bring innovative treatments to those with cystic fibrosis," stated Reshma Kewalramani, M.D., CEO and President of Vertex. "For over two decades, we have been committed to addressing the root cause of cystic fibrosis, expanding treatment options, and enhancing CFTR function for sufferers. Alyftrek, with its convenient once-daily dosing, efficacy across 31 additional mutations, and superior reductions in sweat chloride levels compared to TRIKAFTA, advances us further towards this goal."The approval is based on data from the most comprehensive Phase 3 program ever conducted for cystic fibrosis, involving over 1,000 patients from more than 20 countries and 200 sites."In Phase 3 trials, across diverse genotypes, once-daily Alyftrek demonstrated non-inferiority in ppFEV1 response and a statistically significant improvement in sweat chloride levels compared to TRIKAFTA," noted Dr. Claire L. Keating, Co-Director of the Gunnar Esiason Adult Cystic Fibrosis and Lung Program at Columbia University and a key investigator in the Alyftrek clinical trials. "Alyftrek offers promising potential for enhancing patient care."Alyftrek is also being reviewed by health authorities in the European Union, the United Kingdom, Canada, Switzerland, Australia, and New Zealand for potential approval.The material has been provided by InstaForex Company - www.instaforex.com